Yutao Liu1, Yan Li2, Qiuxiang Ou3, Xue Wu3, Xiaonan Wang4, Yang W Shao5, Jianming Ying6. 1. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. 4. Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China. 5. Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China. 6. Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: jmying@cicams.ac.cn.
Abstract
OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) patients. However, acquired resistance inevitably develops. Comprehensive and dynamic companion genomic diagnosis can gain insights into underlying resistance mechanisms, thereby help oncologists and patients to make informed decision on the potential benefit of the treatment. MATERIALS AND METHODS: A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery. The EGFR mutational status of individual metastatic lesion was determined by genetic testing of the tumor tissue biopsies using next generation sequencing (NGS) throughout the patient's clinical course. An acquired potentially drug-resistant EGFR mutation was functionally validated in vitro and its sensitivity to different EGFR TKIs was assessed simultaneously. RESULTS: We have identified distinct resistance mechanisms to EGFR blockade in different metastatic lung lesions. Acquired EGFR T790M was first detected that leads to the resistance to the gefitinib treatment. Consequently, osimertinib was administrated and the response lasted until disease progressed. We identified a newly acquired EGFR L718V mutation in one lesion in conjunction with L858R, but not T790M, which showed stable disease on the following erlotinib treatment, while EGFR C797S together with L858R/T790M was detected in the other lesion that continuously progressed. In vitro functional studies demonstrated that EGFR-L858R/L718V confers resistance to osimertinib, but retains sensitivity to the second generation TKI afatinib. CONCLUSION: We reported that distinct resistance mechanisms could arise in different metastases within the same patient in response to EGFR blockade. We also demonstrated in vitro that EGFR L718V mutation mediates resistance to osimertinib, but retains sensitivity to afatinib. We evidenced that dynamic companion genomic diagnosis offers valuable information to help define the mechanisms of drug resistance and to guide the selection of subsequent treatment.
OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) patients. However, acquired resistance inevitably develops. Comprehensive and dynamic companion genomic diagnosis can gain insights into underlying resistance mechanisms, thereby help oncologists and patients to make informed decision on the potential benefit of the treatment. MATERIALS AND METHODS: A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery. The EGFR mutational status of individual metastatic lesion was determined by genetic testing of the tumor tissue biopsies using next generation sequencing (NGS) throughout the patient's clinical course. An acquired potentially drug-resistant EGFR mutation was functionally validated in vitro and its sensitivity to different EGFR TKIs was assessed simultaneously. RESULTS: We have identified distinct resistance mechanisms to EGFR blockade in different metastatic lung lesions. Acquired EGFR T790M was first detected that leads to the resistance to the gefitinib treatment. Consequently, osimertinib was administrated and the response lasted until disease progressed. We identified a newly acquired EGFR L718V mutation in one lesion in conjunction with L858R, but not T790M, which showed stable disease on the following erlotinib treatment, while EGFR C797S together with L858R/T790M was detected in the other lesion that continuously progressed. In vitro functional studies demonstrated that EGFR-L858R/L718V confers resistance to osimertinib, but retains sensitivity to the second generation TKI afatinib. CONCLUSION: We reported that distinct resistance mechanisms could arise in different metastases within the same patient in response to EGFR blockade. We also demonstrated in vitro that EGFR L718V mutation mediates resistance to osimertinib, but retains sensitivity to afatinib. We evidenced that dynamic companion genomic diagnosis offers valuable information to help define the mechanisms of drug resistance and to guide the selection of subsequent treatment.
Authors: D Hernandez; M Do Carmo; L Brenan; N S Persky; O Cohen; S Kitajima; U Nayar; A Walker; S Pantel; Y Lee; J Cordova; M Sathappa; C Zhu; T K Hayes; P Ram; P Pancholi; T S Mikkelsen; D A Barbie; X Yang; R Haq; F Piccioni; D E Root; C M Johannessen Journal: Nat Struct Mol Biol Date: 2020-01-10 Impact factor: 15.369
Authors: Gina M Castellano; Joseph Aisner; Stephen K Burley; Brinda Vallat; Helena A Yu; Sharon R Pine; Shridar Ganesan Journal: J Thorac Oncol Date: 2019-06-27 Impact factor: 15.609
Authors: Anna Truini; Jacqueline H Starrett; Tyler Stewart; Kumar Ashtekar; Zenta Walther; Anna Wurtz; David Lu; Jin H Park; Michelle DeVeaux; Xiaoling Song; Scott Gettinger; Daniel Zelterman; Mark A Lemmon; Sarah B Goldberg; Katerina Politi Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Jacqueline H Starrett; Alexis A Guernet; Maria Emanuela Cuomo; Kamrine E Poels; Iris K van Alderwerelt van Rosenburgh; Amy Nagelberg; Dylan Farnsworth; Kristin S Price; Hina Khan; Kumar Dilip Ashtekar; Mmaserame Gaefele; Deborah Ayeni; Tyler F Stewart; Alexandra Kuhlmann; Susan M Kaech; Arun M Unni; Robert Homer; William W Lockwood; Franziska Michor; Sarah B Goldberg; Mark A Lemmon; Paul D Smith; Darren A E Cross; Katerina Politi Journal: Cancer Res Date: 2020-03-19 Impact factor: 12.701
Authors: Noura J Choudhury; Alex Makhnin; Yosef Y Tobi; Robert M Daly; Isabel R Preeshagul; Afsheen N Iqbal; Linda S Ahn; Sara A Hayes; Glenn Heller; Mark G Kris; Gregory J Riely; Helena A Yu Journal: JCO Precis Oncol Date: 2021-04-22